{"name":"Chengdu Suncadia Medicine Co., Ltd.","slug":"chengdu-suncadia-medicine-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HRS-5965","genericName":"HRS-5965","slug":"hrs-5965","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HRS-5965 tablets","genericName":"HRS-5965 tablets","slug":"hrs-5965-tablets","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"HRS-5965","genericName":"HRS-5965","slug":"hrs-5965","phase":"phase_3","mechanism":"HRS-5965 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"HRS-5965 tablets","genericName":"HRS-5965 tablets","slug":"hrs-5965-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNc1FiWWhJQVg1OVVxSXc0OVZOQjc5RmNvbklhYWZXdy04ZGFwWkRIcGZPdUV3RmhqRzdfUWV2dTBseVdkQVd6d1pNUlZ1X2FNRTg1N0REbU93U1dzRVZ5RVVhdkhrNE54aG4xZ1RJY0JlOVZabUpwbEJWU3dwdm9OYWJNbWI0T1V1eEhJcjd0WndOX0VQTHRqWE9MYlk1WlBkd0E?oc=5","date":"2025-09-05","type":"deal","source":"BioWorld News","summary":"Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal - BioWorld News","headline":"Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOQk8xcmM1b0pkdXBGS1kzTmZ3MUI2a0dVZDRBc0JMSlR1aEVXT3NfZGFSZ25PdlBvNmhsWEdrZjJkOHdua1lnZU5oaDNHM1lZNVN3NzBSRUpfem9CQU9KcmZtVzFJd2lTTS1TSjNjV0Y5UkdZQy1KRmZQRENvT2Z2NTVUY2FQQ2Jra0hyZ2VkVXBvM3M?oc=5","date":"2025-01-14","type":"pipeline","source":"BioWorld News","summary":"CSPC wins China clearance of new DPP-4 inhibitor - BioWorld News","headline":"CSPC wins China clearance of new DPP-4 inhibitor","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}